A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

NCT02655614 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: GDC-0134
DRUG: Placebo
DRUG: Rabeprazole
DRUG: Midazolam
DRUG: Caffeine

Sponsor

Genentech, Inc.